Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic composition for repairing chondropathy

a technology for chondropathy and therapeutic compositions, applied in the direction of drug compositions, biocide, heterocyclic compound active ingredients, etc., can solve the problems of inability to regenerate chondropathy, extremely low regenerative ability of cartilage, etc., and achieve the effect of reducing irritation at the affection si

Inactive Publication Date: 2004-09-16
MITSUBISHI TANABE PHARMA CORP
View PDF21 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0026] The composition of the present invention for regenerative treatment of cartilage disease can enhance the expression of cartilage matrix protein encoding gene and thereby showing superior matrix production promoting effect on cartilage especially on articular cartilage that has extremely low regenerative activity, and cure cartilage diseases through the regeneration of cartilage.
[0103] Examples of dispersant include nonionic surfactants such as polyoxyethylene sorbitan fatty acid ester (Tween80, Tween60, Nikko Chemicals Co., Ltd.), polyethylene castor oil (HCO-60, HCO-50, Nikko Chemicals Co., Ltd.), cellulose-derived dispersants such as carboxymethyl cellulose sodium, sodium alginate, dextran, sodium hyaluronate, and the like. These dispersants can serve to improve the dispersibility of microspheres and stabilize the elution of an active ingredient. A dispersant can generally be added to a composition at a concentration of 0.01-2 % by weight preferably 0.05-1 % by weight.

Problems solved by technology

As stated above, cartilage is known to have extremely low regenerative ability, and it was considered that, once damaged, the regeneration thereof is almost impossible.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic composition for repairing chondropathy
  • Therapeutic composition for repairing chondropathy
  • Therapeutic composition for repairing chondropathy

Examples

Experimental program
Comparison scheme
Effect test

experimental example 1

Increase of Matrix Production of Articular Chondrocytes

[0111]

1 Test Compounds Compound(1) (10.sup.-5 M or 10.sup.-4 M); Compound(2) (10.sup.-6 M or 10.sup.-5 M); Compound(9) (10.sup.-6 M or 10.sup.-5 M); Compound(11) (10.sup.-6 M); Compound(21) (10.sup.-6 M or 10.sup.-5 M); Compound(27) (10.sup.-6 M or 10.sup.-5 M); Compound(44) (10.sup.-5 M or 10.sup.-4 M);

[0112] (Isolation and Maintenance of Articular Chondrocytes)

[0113] Four NZW line rabbits (Kitayama Labes., Co Ltd.; male; 4-week-old) were sacrificed with bleeding under ether anesthesia and femur knee joints were collected aseptically. The collected knee joints were stored in phosphate buffer (pH 7.2) containing 0.2% glucose and only the cortical layer of knee joint was scrapped with a surgical knife into a 50 ml tube containing phosphate buffer (pH 7.2) containing 0.2% glucose. The collected knee joint cortical layer was cut into as small sections as possible on a dish with a razor and shaken at 37.degree. C. for 15 minutes in ...

experimental example 2

Fractionation of cAMP-Hydrolyzing PDE Expressed in Articular Cartilage

[0117] Four NZW line rabbits (Kitayama Labes., Co Ltd.; male; 4-week-old) were sacrificed with bleeding under ether anesthesia and femur knee joints were collected aseptically. 15 The collected knee joints were stored in phosphate buffer (pH 7.2) containing 0.2% glucose and only the cortical layer of knee joint portion was scrapped with a knife into a 50 ml tube containing phosphate buffer (pH 7.2) containing 0.2% glucose. The collected knee joint cortical layer was cut into as small sections as possible on a dish with a razor, washed with ice-cold phosphate buffer and homogenized with a homogenizer (Polytron: Kinematica A.G.) in homogenization buffer (20 mM Tris-HCl, pH 7.4, 2 mM magnesium acetate, 0.3 mM calcium chloride, 1 mM dithiothreitol, 40 .mu.M leupeptin, 1.3 mM benzamidine, 0.2 mM phenylmethylsulfonyl fluoride and 1 mM sodium azide). The resultant homogenate was centrifuged (100,000.times.g, 60 minutes) ...

experimental example 3

Expression of A Gene Encoding Cartilage Matrix Protein

[0121] Total RNA was extracted with ISOGEN (Nippon Gene Co., Ltd.) from rabbit knee articular chondrocytes cultured for 4 days according to the same manner as Experimental Example 1 in the presence of Compound (1). at a final concentration of 1.times.10.sup.-4 M or 1.times.10.sup.-5 M, and 15 .mu.g of the total RNA was dissolved in 4.5 .mu.l of a sterilized water. This solution was combined with 2 .mu.l of 5.times.MOPS buffer, 3.5 .mu.l of formaldehyde and 10 .mu.l of formamide, and denatured at 90.degree. C. for 15 minutes. The mixture was then electrophoresed on 1% agarose gel in the presence of formaldehyde. After completion of electrophoresis, RNA was transferred to a nylon membrane (Amersham Pharmacia Biotech) overnight by capillary method. The RNA was fixed to the nylon membrane by UV crosslinking and subjected to prehybridization at 60.degree. C. for 2 hours in 50 ml of hybridization solution (6.times.SSC, 5.times.Denhart'...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
concentrationaaaaaaaaaa
molar ratioaaaaaaaaaa
Login to View More

Abstract

A composition for regenerative treatment of cartilage disease, which comprises a PDE4 inhibitor as an active ingredient, specifically a composition comprising a PDE4 inhibitor and a biocompatible and biodegradable polymer is provided, which composition, when formulated into a form suited to administer locally to affected cartilage region, such as microsphere preparation, can provide a pharmaceutical composition showing an excellent effect in regenerative treatment of cartilage.

Description

[0001] The present invention relates to a composition for regenerative treatment of cartilage disease, specifically, to a pharmaceutical composition for regenerative treatment of cartilage disease such as osteoarthrosis (degenerative joint disease), chondrodystrophy, degenerative discopathy or meniscus injury.[0002] Cartilage is considerably elastic that plays a role in the construction of skeleton together with bone and the protection of internal organs. Cartilage tissue consists of chondrocytes and cartilage matrix surrounding the same.[0003] Cartilage is formed by mesenchyme-originated chondroblasts which cells produce matrix in circumference in the process of cell division and growth. The cartilage matrix consists of amorphous matrix and fibrous components, and is classified into the following groups according to the ratio of components: (1) hyaline cartilage (articular cartilage, costicartilage, thyroid cartilage etc.); (2) fibrocartilage (discus intervertebrali, pubic symphysi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/16A61K31/27A61K31/277A61K31/343A61K31/381A61K31/40A61K31/4166A61K31/42A61K31/423A61K31/44A61K31/4409A61K31/4418A61K31/4425A61K31/4453A61K31/4709A61K31/4985A61K31/50A61K31/501A61K31/502A61K31/5025A61K31/519A61K31/522A61K31/5377A61K31/551A61P19/02
CPCA61K9/1647A61K31/551A61K31/277A61K31/343A61K31/381A61K31/40A61K31/4166A61K31/42A61K31/423A61K31/44A61K31/4409A61K31/4418A61K31/4425A61K31/4453A61K31/4709A61K31/4985A61K31/50A61K31/501A61K31/502A61K31/5025A61K31/519A61K31/522A61K31/5377A61K31/27A61P19/00A61P19/02A61P19/08A61P19/10A61P43/00
Inventor TAKIGAWA, MASAHARUSAKURAI, NAOKITAKAGI, TOSHIKIYANAKA, NORIYUKIHORIKIRI, YUJITAMURA, TAKASHI
Owner MITSUBISHI TANABE PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com